Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study.

Leandro Jonata Carvalho OliveiraThais Baccili Cury MegidDaniela Dornelles RosaCarlos Alberto da Silva MaglianoDaniele Xavier AssadDaniel Fontes ArgoloSolange Moraes SanchesLaura TestaJosé BinesRafael KaliksMaira CaleffiDebora de Melo GagliatoMarina SahadeRomualdo Barroso-SousaTatiana Strava CorrêaAndrea Kazumi ShimadaDaniel Negrini BatistaDaniel Musse GomesMarcelle Goldner CescaDébora GaudêncioLarissa Matos Almeida MouraJulio Antonio Pereira de AraújoArtur KatzMax Senna Mano

Published in: Therapeutic advances in medical oncology (2022)

Our study suggests that ODX is cost-saving for patients with high clinical risk HR+/HER2- eBC and cost-attractive for the overall population in the Brazilian private medicine perspective. Its incorporation into routine practice should be strongly considered by healthcare providers.

Keyphrases

healthcare
health insurance
cross sectional
clinical trial
health information
social media